Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.
byBenzinga Newsdesk
July 6, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Expert Ratings for Pfizer

By Benzinga Insights
July 29, 11:36 AM
Over the past 3 months, 4 analysts have published their opinion on Pfizer (NYSE:PFE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

PFE